CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Momordica charantia +1 moredrug
Likely dose
Momordica charantia 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02397447
NCT02397447Phase 2Completed
CompareCT.gov

Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment

University of Guadalajara·interventional·Posted Mar 25, 2015·Updated Oct 22, 2020

In Brief

A Phase 2 clinical trial evaluating Momordica charantia and Placebo for Diabetes Mellitus Type 2. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose, glycated hemoglobin (A1C), and fructosamine were observed. It is unknown whether this improvement is due to an improvement in insulin sensitivity and insulin secretion. The purpose of this study is to evaluate the effect of the administration of Momordica Charantia on insulin sensitivity and insulin secretion in patients with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 25, 2015
Enrollment StartMar 1, 2013
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.3 years ago

Interventions

Momordica charantiadrug

Momordica Charantia: 2000 mg per day for three months

Placebodrug

Placebo: 2000 mg per day for three months